CXCL4 and CXCL4L1 in cancer

Pieter Ruytinx; Paul Proost; Sofie Struyf

doi:10.1016/j.cyto.2018.02.022

CXCL4 and CXCL4L1 in cancer

Cytokine. 2018 Sep:109:65-71. doi: 10.1016/j.cyto.2018.02.022.

Authors

Pieter Ruytinx¹, Paul Proost¹, Sofie Struyf²

Affiliations

¹ KU Leuven, University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Molecular Immunology, B-3000 Leuven, Belgium.
² KU Leuven, University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Molecular Immunology, B-3000 Leuven, Belgium. Electronic address: sofie.struyf@kuleuven.be.

PMID: 29903575
DOI: 10.1016/j.cyto.2018.02.022

Abstract

Chemokines regulate leukocyte migration during physiological and pathological conditions. It is currently accepted that these chemotactic cytokines are also important in the development and progression of cancer. CXCL4 and its non-allelic variant CXCL4L1 are two platelet-associated chemokines that have been attributed anti-tumoral activity as a result of their angiostatic potential and the chemotactic activity for anti-tumoral leukocytes. Here we review the role of CXCL4 and CXCL4L1 in cancer, the use of both chemokines as cancer biomarkers and discuss some possible therapeutic opportunities.

Keywords: CXCL4; CXCL4L1; Chemokines; Tumor.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Cell Proliferation / physiology
Chemotaxis / physiology*
Humans
Lymphocytes, Tumor-Infiltrating / immunology*
Neoplasms / pathology*
Neovascularization, Pathologic / pathology*
Platelet Factor 4 / metabolism*
Tumor Microenvironment / immunology

Substances

PF4 protein, human
PF4V1 protein, human
Platelet Factor 4